Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Full description
The study will be conducted in 2 parts: Part 1 Dose-Ranging and Part 2 Safety Expansion.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
770 participants in 5 patient groups, including a placebo group
Loading...
Central trial contact
Moderna Clinical Trials Support Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal